CD274 and cancer: Cancer immunotherapy with immune checkpoint blockade (ICB) using anti-PD-1/PD-L1 or anti-CTLA4 antibodies enhances antitumor activity of the immune components of the TME, including cytotoxic CD8 positive T cells and natural killer cells [82].